NEWS
New PCMA Podcast Highlights Importance of Prescription Drug Rebates
“The rebate rule came out of a concern about rising drug prices,” said Brill. “But it is a policy that is chock full of unintended consequences. If it were implemented, we’d have fewer discounts. That’s definitely not going to lower overall spending in the healthcare sector.”
Updated MGA Report Presents Biosimilar Market Opportunities in Ophthalmology
MGA releases an updated report, “Biosimilar Market Opportunities in Ophthalmology.”
Health Care Jobs Gap Remains Serious
Employment in the health care sector increased by 56,700 in June, more than double the average monthly pace in this sector during the last year, according to last Friday’s jobs report.
MGA Releases Economic Impact Report for Multinational Pharmaceutical Company
In a newly released report, MGA highlights the broad economic impact of Otsuka Pharmaceutical in the U.S. operations.
‘The Price of Business’: Discussing Today’s Political and Economic Environment
On June 8, Alex Brill joined Kevin Price on ‘The Price of Business’ discussing today’s political and economic environment. Brill shared his sentiments on the economic outlook.
New MGA Report Presents Biosimilar Market Opportunities in Ophthalmology
MGA releases a new report, “Biosimilar Market Opportunities in Ophthalmology.”
Alex Brill to FTC: Claims That PBMs Raise Drug Prices are Unfounded
In response to the FTC’s request for information regarding the business practices of pharmacy benefit managers (PBMs) and their impact on pharmacies and consumers, MGA’s Alex Brill submitted a letter detailing his findings.
Do Tax Cuts Cause Inflation? Alex Brill on ‘The Price of Business’
On May 11, Alex Brill joined Kevin Price on his radio show, “The Price of Business,” to talk about whether tax cuts cause inflation. The short answer is: It depends.
‘The Price of Business’: Alex Brill Talks Rising Inflation
On April 21, Alex Brill made a special appearance on “The Price of Business” radio show to talk about the sharp rise of inflation and its effects on small businesses and individuals earning low wages.
Massachusetts’s Proposed ‘Millionaires’ Tax’ Will Push up the Federal Deficit
There is a proposed tax change in Massachusetts that should have all who are interested in fiscal policy concerned. In November, Bay State voters will decide whether to adopt an amendment to the state constitution imposing a 4 percent surtax on annual taxable income above $1 million starting in 2023.
Charitable Giving is Good. Be Smart About how to Encourage It.
In 2020, Americans’ individual charitable giving reached $324 billion, a record high and a 2.2 percent increase from 2019. While the pandemic imposed great costs on our society, many households shared their resources with others, including religious, educational, and human service organizations.
MGA Report Cited in Forbes Article on Rising Prescription Drug Prices
In his Forbes article, Ike Brannon discusses the blame game being played in Washington in regards to skyrocketing drug prices. MGA’s report “Understanding Drug Rebates and Their Role in Promoting Competition” was utilized by Brannon to bolster the argument that it is the drug companies who are responsible for drug pricing.
New Report from MGA Examines Impact of Rebates on Drug Pricing, Competition
MGA has released a new report today, “Understanding Drug Rebates and Their Role in Promoting Competition,” authored by founder and CEO Alex Brill.
The Great Resignation: Alex Brill Shares Insights on i24News
A record number of people are quitting their jobs across all employment sectors. Alex Brill joins i24News to discuss what the skyrocketing quit rates means for the US economy, and when we can expect the job market to return to normal.
Patent Thickets Constrain US Biosimilars Market
Biosimilars represent a significant cost-savings opportunity in the United States because they can introduce competition for some of the most expensive and widely used prescription drugs on the market: originator biologics. Several market and regulatory barriers have slowed biosimilar market entry and uptake in the United States.
- Don’t Mix US Tax Administration Policy with the Israel-Hamas Conflict
- The Economics of “Delinking” PBM Compensation
- The Supreme Court Should Leave the Tax Code Alone
- Implications of Cannabis Legalization for the US Federal Budget
- Amicus Brief in Moore v. United States
- Biosimilars – Keys to Success in the Pharmacy Benefit
- New MGA White Paper Examines Consequences of Regulatory Uncertainty for Employee Ownership
- MGA Releases White Paper on Role of PBMs in US Drug Pricing Debate
- Unintended Consequences of Limiting PBMs
- ‘The Price of Business’: A Major Fiscal Crisis is Brewing and Largely Ignored by the Media
